NCT00490737View on ClinicalTrials.gov

Safety Study to Evaluate Daptomycin in Non-infected Adults Who Are Either on Hemodialysis or Continuous Ambulatory Peritoneal Dialysis (MK-3009-021)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 12, 2007

Primary Completion Date

May 12, 2008

Study Completion Date

May 12, 2008

Conditions

End-Stage Renal Disease

Interventions

DRUG

daptomycin

6mg/kg, i.v. infusion over 30 minutes; every 48 hours for a total of 3 doses

All Listed Sponsors

lead

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT00490737 - Safety Study to Evaluate Daptomycin in Non-infected Adults Who Are Either on Hemodialysis or Continuous Ambulatory Peritoneal Dialysis (MK-3009-021) | Biotech Hunter | Biotech Hunter